Blocking the PVR-TIGIT axis has demonstrated enhanced anti-tumor immune responses across various cancer types [36], and preclinical data suggest that targeting this pathway could also improve immune responses in neuroblastoma [24]. Here, PVR is linked to neuroblastoma.